BACKGROUND: Hepatitis C virus (HCV) and hepatitis B virus (HBV) are not only hepatotropic, but also lymphotropic viruses. Recently, some reports suggested that these viruses may participate in the development of malignant lymphoproliferative disorders. METHODS: We investigated the prevalence of HCV or HBV infection in 348 patients with non-Hodgkin's lymphoma (NHL). We also compared these prevalences with those in blood donors as a control group representing the general population in our area (n= 1,513,358). Next, we evaluated the clinical and pathologic characteristics of HCV- or HBV-infected NHL cases. Non-Hodgkin's lymphoma was classified according to the Working Formulation classification. RESULTS: Thirty-seven cases (14.9%) were found to be infected with HCV or HBV; of these, 20 (8.1%) were infected with HCV, and 17 (6.9%) with HBV. In male NHL patients, the rate of HCV infection was significantly higher than in an age- and sex-matched population in the same area (P < 0.001, Mantel-Haenszel test). The rate of HBV infection also tended to be higher in the population (P = 0.0551). In contrast, in female NHL patients, the rate of HCV or HBV infection was not higher than in the general population. In HCV-infected cases, 15 cases (75%) had B-cell NHL and 16 cases (80%) were classified as being in the intermediate grade; B-cell NHL comprised 83% of all NHL cases. In HBV-infected NHL cases, 11 (65%) were of B-cell type and 10 (58%) were classified as being in the intermediate grade. CONCLUSIONS: The high prevalence of HCV or HBV infections in our study population provides epidemiologic evidence suggesting that HCV and HBV infections may be involved in the development of a subgroup of NHL in males. Our investigation also revealed that both HCV- and HBV-infected NHL patients showed certain similarities in clinical and pathologic manifestations.
BACKGROUND:Hepatitis C virus (HCV) and hepatitis B virus (HBV) are not only hepatotropic, but also lymphotropic viruses. Recently, some reports suggested that these viruses may participate in the development of malignant lymphoproliferative disorders. METHODS: We investigated the prevalence of HCV or HBV infection in 348 patients with non-Hodgkin's lymphoma (NHL). We also compared these prevalences with those in blood donors as a control group representing the general population in our area (n= 1,513,358). Next, we evaluated the clinical and pathologic characteristics of HCV- or HBV-infected NHL cases. Non-Hodgkin's lymphoma was classified according to the Working Formulation classification. RESULTS: Thirty-seven cases (14.9%) were found to be infected with HCV or HBV; of these, 20 (8.1%) were infected with HCV, and 17 (6.9%) with HBV. In male NHL patients, the rate of HCV infection was significantly higher than in an age- and sex-matched population in the same area (P < 0.001, Mantel-Haenszel test). The rate of HBV infection also tended to be higher in the population (P = 0.0551). In contrast, in female NHL patients, the rate of HCV or HBV infection was not higher than in the general population. In HCV-infected cases, 15 cases (75%) had B-cell NHL and 16 cases (80%) were classified as being in the intermediate grade; B-cell NHL comprised 83% of all NHL cases. In HBV-infected NHL cases, 11 (65%) were of B-cell type and 10 (58%) were classified as being in the intermediate grade. CONCLUSIONS: The high prevalence of HCV or HBV infections in our study population provides epidemiologic evidence suggesting that HCV and HBV infections may be involved in the development of a subgroup of NHL in males. Our investigation also revealed that both HCV- and HBV-infected NHLpatients showed certain similarities in clinical and pathologic manifestations.
Authors: Pierluigi Cocco; Giovanna Piras; Maria Monne; Antonella Uras; Attilio Gabbas; Maria G Ennas; Angelo Palmas; Marco Murineddu; Stefania Collu; Massimo Melis; Marco Rais; Pierfelice Todde; Maria G Cabras; Emanuele Angelucci; Giovannino Massarelli; Alexandra Nieters Journal: Int J Hematol Date: 2008-05-01 Impact factor: 2.490
Authors: Nikolaus Becker; Paul Schnitzler; Paolo Boffetta; Paul Brennan; Lenka Foretova; Marc Maynadié; Alexandra Nieters; Anthony Staines; Yolanda Benavente; Pierluigi Cocco; Silvia de Sanjose Journal: J Cancer Res Clin Oncol Date: 2012-07-06 Impact factor: 4.553
Authors: Lesley A Anderson; Ruth Pfeiffer; Joan L Warren; Ola Landgren; Shahinaz Gadalla; Sonja I Berndt; Winnie Ricker; Ruth Parsons; William Wheeler; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-10-28 Impact factor: 4.254
Authors: Nikolaus Becker; Joan Fortuny; Tomas Alvaro; Alexandra Nieters; Marc Maynadié; Lenka Foretova; Anthony Staines; Paul Brennan; Paolo Boffetta; Pier Luigi Cocco; Silvia de Sanjose Journal: J Cancer Res Clin Oncol Date: 2009-02-11 Impact factor: 4.553
Authors: Vahap Okan; Mehmet Yilmaz; Aysen Bayram; Cem Kis; Sami Cifci; Hakan Buyukhatipoglu; Mustafa Pehlivan Journal: Int J Hematol Date: 2008-10-04 Impact factor: 2.490